Dexlansoprazole MR.
BACKGROUND
Proton pump inhibitors (PPIs) have been used for more than two decades to control symptoms of gastroesophageal illnesses. Studies have shown that most PPIs do not provide 24-h symptom control, and that can be the reason for treatment failure. Recently, dexlansoprazole dual delayed release (DDR) (Takeda Pharmaceuticals North America, Inc., USA) under the trade name of Kapidex (Takeda Pharmaceutical Company Limited, Japan) came onto the market to provide longer duration of action and more effective acid suppression.


OBJECTIVE
The purpose of this paper is to discuss the pharmacology of dexlansoprazole DDR and to provide a concise review of all available studies showing its efficacy. The combination of the slower metabolism of the R-enantiomer and novel dual release pharmacokinetics is impressive.


METHODS
This manuscript is based on a review of all currently available medical literature on dexlansoprazole DDR.


CONCLUSIONS
Dexlansoprazole DDR has the potential to outperform traditional PPIs based on the metabolism and novel pharmacokinetics. It is currently FDA approved for the treatment of erosive esophagitis (acute, maintenance) and symptomatic gastroesophageal reflux disease.
Aslam
Naeem
N
University of Louisville, Division of Gastroenterology/Hepatology, Department of Medicine, Kentucky 40292, USA.
Wright
Richard
R
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics*; D000208:Acute Disease; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations / Q000378:metabolism / Q000493:pharmacokinetics; D064748:Dexlansoprazole; D004942:Esophagitis, Peptic / Q000188:drug therapy; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006801:Humans; D064747:Lansoprazole; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D003692:Delayed-Action Preparations; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064748:Dexlansoprazole